earnings
confidence high
sentiment neutral
materiality 0.75
Bio-Techne Q4 revenue $321M, adjusted EPS $0.52; dividend $0.08; Merck deal on track
BIO-TECHNE Corp
- Q4 revenue $321.2M (+1% reported, +3% organic); FY26 flat at $1.2B
- Q4 GAAP EPS $0.35 vs $(0.11) prior year; adjusted EPS $0.52 vs $0.53
- FY26 GAAP EPS $1.16 vs $0.46; adjusted EPS $1.93 vs $1.92
- Quarterly dividend $0.08/share, payable Sept 4, 2026, record Aug 24
- Merck KGaA acquisition at $73/share cash, ~$11.3B EV, on track